Search hospitals

>

California

>

Palo Alto

Stanford Cancer Institute Palo Alto

Claim this profile

Palo Alto, California 94304

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Cancer

Conducts research for Lymphoma

Conducts research for Pancreatic Cancer

556 reported clinical trials

67 medical researchers

Photo of Stanford Cancer Institute Palo Alto in Palo AltoPhoto of Stanford Cancer Institute Palo Alto in Palo AltoPhoto of Stanford Cancer Institute Palo Alto in Palo Alto

Summary

Stanford Cancer Institute Palo Alto is a medical facility located in Palo Alto, California. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Lymphoma, Pancreatic Cancer and other specialties. Stanford Cancer Institute Palo Alto is involved with conducting 556 clinical trials across 590 conditions. There are 67 research doctors associated with this hospital, such as Andrei Iagaru, MD, Robert Lowsky, MD, Christopher Chen, and Lori Muffly, MD.

Area of expertise

1

Breast Cancer

Global Leader

Stanford Cancer Institute Palo Alto has run 77 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive
2

Lung Cancer

Global Leader

Stanford Cancer Institute Palo Alto has run 71 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at Stanford Cancer Institute Palo Alto

Lung Cancer

Breast Cancer

Cancer

Skin Cancer

Ovarian Cancer

Prostate Cancer

Breast cancer

Uterine Cancer

Chronic Lymphocytic Leukemia

Bladder Cancer

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Radiation Therapy

for Brain Metastasis

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting

2 awards

Phase 3

31 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Stanford Cancer Institute Palo Alto?

Where is Stanford Cancer Institute Palo Alto located?

Who should I call to ask about financial aid or insurance network?

What insurance does Stanford Cancer Institute Palo Alto accept?

What awards or recognition has Stanford Cancer Institute Palo Alto received?